Lucid Capital Markets initiated coverage of Lensar (NASDAQ: LNSR) with a “buy” rating and price target of $11.00. The stock closed at $6.92 on September 25.
Lensar designs, manufactures, and commercializes femtosecond laser systems used in cataract surgery and the management of pre-existing or surgically induced corneal astigmatism. The company operates as a single-segment medical device business built around two platforms: the legacy Lensar Laser System (LLS) and its successor, the Ally Robotic Cataract Laser System. Ally received FDA clearance in June 2022 and launched commercially in August 2022 as a ground-up redesign meant to solve the workflow and precision limitations of first-generation femtosecond lasers. Ally is now the company’s flagship platform and the primary driver of its commercial results, sold alongside a razor/razor-blade consumable model of patient interface device (PID) kits and per-procedure licenses.
Alcon (NYSE/SWX: ALC) agreed to acquire Lensar in March 2025 at $14.00/ share (~$356M in equity value, up to $16.75/share or ~$430M equity value when including a contingent value right). Alcon was getting access to Lensar’s second generation laser platform, which it could bundle with its premium IOLs. FTC viewed the tie-up as anti-competitive (Alcon also owns a first-generation laser platform and would control ~50% of the market). On March 16, 2026 the parties walked and Lensar kept the $10.0M deposit. LNSR shares fell on the news, bottomed near $6, and at $8 still sit at a little over half the cash consideration alone. That deal also created some short-term disruption as sales reps were distracted and distributors focused elsewhere.
Analyst Alex Nowak writes, “This is the near-term stock opportunity: refocus on Ally post-Alcon deal termination, resume the pre-deal placement cadence, continue to generate double-digit recurring revenue growth, and potentially bolt-on other ocular/cataract assets or seek a premium IOL company without an existing entrenched laser franchise.”
Mr. Nowak adds, “We are watching five things: 1) The rebuild of the commercial organization that was disrupted during a year in merger limbo; 2) A return to the mid-teens placements per quarter cadence of late 2025, or the ~20 per quarter of 2024; 3) The international re-ramp as disruptors begin selling Ally again not fearing an Alcon-related impact; 4) The first real competitive launch of a laser that matches some, but not all of Ally’s workflow advantages. Bausch + Lomb’s SeeLyra just received CE mark and U.S. approval is in-progress (exact timing not announced), which only improves on image/guidance and soft docking. It still does not solve the two-room problem. 5) Greater visibility on what Lensar wants to become longer-term. Does the company want to remain a single-product laser company or wish to become a larger ocular/cataract player with add-on products. Lensar is a viable standalone business and share/penetration figures show it can become very large, replacing manual cataract approaches. Plus, the FTC record makes Alcon, J&J, and Bausch + Lomb unlikely acquirers, so any takeout optionality should be reserved for a strategic without an existing femtosecond platform. Lensar also makes perfect sense with an ocular company with other cataract assets that could be sold along Ally (as long as it did not also have a laser). The other path is Lensar bolting on products to its channel as well as R&D to bring its current product to new avenues. We look for more clarity on these paths as the company re-emerges to public investors post-deal termination.”
